Consenting women with evidence of poor ovarian reserve will be randomly assigned to treatment with either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP).
Consenting women with evidence of poor ovarian reserve will be randomly assigned to treatment with either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP).
Ovarian Function Following Intraovarian Injection of PRP
-
Center for Human Reproduction, New York, New York, United States, 10021
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
21 Years to 44 Years
FEMALE
Yes
Center for Human Reproduction,
David H Barad, MD, PRINCIPAL_INVESTIGATOR, Center for Human Reproduction
2026-06-30